This randomized, double-blind, phase 2 study aimed to investigate the efficacy and safety of secukinumab as compared to placebo in 41 subjects with moderate-to-severe AD over a 16-week period, with evaluations of clinical outcomes and molecular and cellular profiles in skin. SOURCE: Emma Guttman-Yassky (emma.guttman@mountsinai.org) - Emma Guttman Icahn School of Medicine at Mount Sinai

Pluto Bioinformatics

GSE137430: A Phase 2 Randomized, Double-blind Pilot Study of IL-17-Targeting with 2 Secukinumab in Moderate-to-Severe Atopic Dermatitis